Coeptis Therapeutics Hldgs Inc (COEP) Stock Price, Quote & News

Company Profile

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, natural killer cell therapy technology. Its product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-rela...

Industry: Biotechnology

Sector: Healthcare

Phone: 724 934 6467

Website: coeptistx.com

Address:

105 Bradford Road, Suite 420, Wexford, United States

BlazingStocks Jun. 12 at 7:15 PM

$BURU - NUBURU is also actively advancing its Transformation Plan, which emphasizes the adoption of exponential technologies, including artificial intelligence (AI) and robotics by leveraging the strategic partnership with COEPTIS' NexGenAI Affiliates Network ( NASDAQ: $COEP ), with particular reference to the SaaS Business and the Blue-Laser technology go-to-market. https://finance.yahoo.com/news/nuburu-files-100m-sec-registration-122000523.html

0 · Reply

NEWBIGTECH Jun. 7 at 1:16 AM

$COEP

1 · Reply

BlazingStocks May. 29 at 7:24 PM

0 · Reply

OpenOutcrier May. 28 at 12:30 PM

$COEP (+8.7% pre) Coeptis Therapeutics (COEP): Monarch Therapeutics and SNAP Biosciences Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology https://ooc.bz/l/66057

0 · Reply

AceFurley May. 27 at 3:02 PM

$COEP Wasnt the price target $50 a couple months ago?

0 · Reply

NEWBIGTECH May. 27 at 1:53 PM

$COEP

0 · Reply

makedatbread88 May. 27 at 1:16 PM

Made a list of “crypto reserve” stocks that haven’t had massive runs yet. MARK this post one of these will run HUGE near term. Eyes on these tickers 👇 $PSQH $GRYP $TRNR $SUNE $COEP

1 · Reply

NEWBIGTECH May. 26 at 3:50 PM

$COEP https://www.nasdaq.com/articles/coeptis-therapeutics-holdings-inc-enters-definitive-merger-agreement-z-squared-inc-pursue#:~:text=Quiver%20AI%20Summary,the%20growing%20digital%20asset%20market.

0 · Reply

NEWBIGTECH May. 26 at 3:48 PM

$COEP "We are excited to take this step towards our goal of creating the largest publicly-traded company in the United States primarily focused on DOGE mining," We’re proud of our strategy to bring retail and institutional audiences alike in the public markets a focused exposure to a DOGE asset that currently has over $20B in market capitalization. We believe we have assembled a stellar team that has the requisite expertise and infrastructure."

0 · Reply

NEWBIGTECH May. 26 at 3:38 PM

$COEP . In connection with the merger, Coeptis intends to spin out its biopharmaceutical operations, and continue to operate those operations separate from Coeptis after the merger. The technology operations will remain in the Company after the merger. Assuming all conditions to closing are satisfied, the close of the transaction is anticipated to occur in the third quarter of 2025. It is anticipated that Coeptis will be rebranded and operate as Z Squared, Inc., and is expected to list on the Nasdaq Capital Market.

0 · Reply

Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology

Apr 25, 2025, 8:33 AM EDT - 7 weeks ago

Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement

Apr 17, 2025, 8:38 AM EDT - 2 months ago

COEPTIS Partners with NexGenAI Solutions Group to Launch New AI Co-Working Hub in India, Driving Global Innovation in Technology

Mar 11, 2025, 8:34 AM EDT - 3 months ago

Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline

Mar 7, 2025, 8:37 AM EST - 3 months ago

COEPTIS' NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan

Mar 6, 2025, 8:00 AM EST - 3 months ago

NUBURU Partners With COEPTIS NexGenAI Affiliates Network to Drive Innovation in AI and Robotics as Part of Its Transformation Plan

BURU

Feb 20, 2025, 9:00 AM EST - 4 months ago

COEPTIS' NexGenAI Partners with Arketyp Valu to Revolutionize Digital Engagement on the Verus Network

Feb 20, 2025, 7:27 AM EST - 4 months ago

COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing

Feb 13, 2025, 8:39 AM EST - 4 months ago

COEPTIS Announces the Launch of COEP Venture Group to Invest in AI, RPA, and AI Agent Startups

Feb 6, 2025, 8:08 AM EST - 4 months ago

COEPTIS Completes $10 Million Series A Preferred Financing Round, Reinforcing Commitment to Technological Innovation and AI Integration

Jan 30, 2025, 8:27 AM EST - 4 months ago

Coeptis Therapeutics Holdings Becomes COEPTIS: Embracing a Future of Technology and Innovation

Jan 23, 2025, 8:09 AM EST - 5 months ago

Coeptis Therapeutics Leverages Artificial Intelligence and Blockchain for Next-Generation Innovation

Jan 22, 2025, 8:00 AM EST - 5 months ago

Coeptis Therapeutics Regains Compliance with Nasdaq Listing Rule 5550(a)(2)

Jan 7, 2025, 8:00 AM EST - 5 months ago

Coeptis Therapeutics Announces First Customer Adoptions of its NexGenAI Marketing Platform

Dec 27, 2024, 8:15 AM EST - 6 months ago

Coeptis Therapeutics Announces Reverse Stock Split

Dec 26, 2024, 8:15 AM EST - 6 months ago

Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies

Dec 12, 2024, 8:00 AM EST - 6 months ago

Coeptis Therapeutics Unveils New Technology Division: Coeptis Technologies

Dec 3, 2024, 8:15 AM EST - 6 months ago

Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries

Nov 7, 2024, 8:07 AM EST - 7 months ago

Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development

Oct 24, 2024, 8:07 AM EDT - 8 months ago

Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use

Oct 15, 2024, 8:07 AM EDT - 8 months ago

Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy

Sep 19, 2024, 7:07 AM EDT - 9 months ago

Coeptis Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Sep 5, 2024, 8:07 AM EDT - 10 months ago

Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to Shareholders

Jun 20, 2024, 8:47 AM EDT - 1 year ago

Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering

May 30, 2024, 8:47 AM EDT - 1 year ago

Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting

May 8, 2024, 8:47 AM EDT - 1 year ago

Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024

May 2, 2024, 8:47 AM EDT - 1 year ago

Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting

Apr 2, 2024, 8:47 AM EDT - 1 year ago

Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award

Feb 26, 2024, 9:00 AM EST - 1 year ago

Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK

Feb 7, 2024, 7:30 AM EST - 1 year ago

Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections

Jan 4, 2024, 7:30 AM EST - 1 year ago

Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024

Dec 4, 2023, 7:30 AM EST - 1 year ago

Coeptis Therapeutics to Present at the Emerging Growth Conference

Oct 31, 2023, 9:01 AM EDT - 1 year ago

Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023

Oct 24, 2023, 8:30 AM EDT - 1 year ago

Coeptis Therapeutics Announces $2 Million Private Placement

Oct 11, 2023, 7:30 AM EDT - 1 year ago

Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology

Oct 9, 2023, 9:15 AM EDT - 1 year ago

Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies

Oct 4, 2023, 7:30 AM EDT - 1 year ago

Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting

Sep 27, 2023, 7:30 AM EDT - 1 year ago

Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa

$Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection$

Sep 14, 2023, 7:30 AM EDT - 1 year ago

Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection

Sep 11, 2023, 7:30 AM EDT - 1 year ago

Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowment

Aug 30, 2023, 1:00 PM EDT - 1 year ago

Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer

Aug 17, 2023, 7:30 AM EDT - 1 year ago

Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics

Aug 1, 2023, 8:00 AM EDT - 2 years ago

Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic

Jun 16, 2023, 4:00 PM EDT - 2 years ago

Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering

Jun 14, 2023, 9:28 AM EDT - 2 years ago

Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten Offering

Jun 9, 2023, 7:00 AM EDT - 2 years ago

Coeptis Therapeutics Receives Approval to Transfer to The Nasdaq Capital Market

May 17, 2023, 8:30 AM EDT - 2 years ago

Coeptis Therapeutics Appoints Brian Cogley as Chief Financial Officer

May 10, 2023, 3:00 PM EDT - 2 years ago

Coeptis Therapeutics' SNAP-CAR Technology Platform for Programmable Antigen Targeting Featured in Peer-Reviewed Article in Nature Communications

Apr 18, 2023, 7:30 AM EDT - 2 years ago

Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra Therapeutics

BlazingStocks Jun. 12 at 7:15 PM

0 · Reply

NEWBIGTECH Jun. 7 at 1:16 AM

$COEP

1 · Reply

BlazingStocks May. 29 at 7:24 PM

0 · Reply

OpenOutcrier May. 28 at 12:30 PM

$COEP (+8.7% pre) Coeptis Therapeutics (COEP): Monarch Therapeutics and SNAP Biosciences Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology https://ooc.bz/l/66057

0 · Reply

AceFurley May. 27 at 3:02 PM

$COEP Wasnt the price target $50 a couple months ago?

0 · Reply

NEWBIGTECH May. 27 at 1:53 PM

$COEP

0 · Reply

makedatbread88 May. 27 at 1:16 PM

Made a list of “crypto reserve” stocks that haven’t had massive runs yet. MARK this post one of these will run HUGE near term. Eyes on these tickers 👇 $PSQH $GRYP $TRNR $SUNE $COEP

1 · Reply

NEWBIGTECH May. 26 at 3:50 PM

$COEP https://www.nasdaq.com/articles/coeptis-therapeutics-holdings-inc-enters-definitive-merger-agreement-z-squared-inc-pursue#:~:text=Quiver%20AI%20Summary,the%20growing%20digital%20asset%20market.

0 · Reply

NEWBIGTECH May. 26 at 3:48 PM

0 · Reply

NEWBIGTECH May. 26 at 3:38 PM

0 · Reply

MALO_MY_BOY May. 24 at 1:51 PM

$COEP

0 · Reply

tarwc May. 23 at 7:17 PM

$COEP https://b.tc/conference/2025 Management from Z Squared and COEP will be attending this conference and will be answering questions regarding the 9,000 doge/lite coin mining machines from crypto fund managers/influencers alike. Stay tuned. https://b.tc/conference/2025

1 · Reply

NEWBIGTECH May. 21 at 2:03 PM

$COEP $SLS

0 · Reply

BlazingStocks May. 19 at 7:23 PM

$BURU - Let's see a red to green Power Hour! NUBURU is also actively advancing its Transformation Plan, which emphasizes the adoption of exponential technologies, including artificial intelligence (AI) and robotics by leveraging the strategic partnership with COEPTIS' NexGenAI Affiliates Network (NASDAQ: $COEP), with particular reference to the SaaS Business and the Blue-Laser technology go-to-market. https://finance.yahoo.com/news/nuburu-files-100m-sec-registration-122000523.html

0 · Reply

neverending May. 17 at 5:18 PM

$COEP is v 6tg

1 · Reply

BinaryLogic May. 16 at 1:13 AM

$COEP

0 · Reply

NEWBIGTECH May. 13 at 2:49 PM

$COEP Undervalued.

0 · Reply

NEWBIGTECH May. 13 at 2:47 PM

$COEP Undervalued.

0 · Reply

MALO_MY_BOY May. 12 at 6:37 PM

$DOGE.X $COEP

0 · Reply

BinaryLogic May. 11 at 12:40 PM

$COEP Thoughtful investors had recommended this Company and its stock to me over the last 5-6mos, but I stayed back waiting for a better opportunity. I started on the fallout following the merger news (below), at/around $7.0-8.0 which aligned with the Bull flag baseline on the 1YR Daily. Admittedly-the merger/deal has many tails that leave me guided, but I presumed a reversal of some sort from the fallout to these levels. https://finance.yahoo.com/news/doge-mining-firm-z-squared-181829870.html?fr=sycsrp_catchall

0 · Reply

BinaryLogic May. 11 at 12:35 PM

$RGLS $DRUG $COEP $SMMT $MNPR [Correct] Investors only had to wait 4mos to 7X on RGLS. The Novartis acquisition (below) creates a baseline (guaranteed) $7.0 floor with an additional (contingent value right) $7.0/sh incremental on successful milestone completion. https://www.prnewswire.com/news-releases/regulus-therapeutics-enters-into-agreement-to-be-acquired-by-novartis-ag-302442023.html

1 · Reply

MALO_MY_BOY May. 10 at 2:23 PM

$DOGE.X $COEP

0 · Reply

Market Cap	29.38M
Revenue (ttm)	0.00
Net Income (ttm)	-10.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.02

Volume	5,000
Avg Vol	57,908
Day's Range	N/A - N/A
Shares Out	3.51M
Stochastic %K	13%
Beta	-0.59
Analysts	Strong Buy
Price Target	$3.00